Navigation Links
IntegenX Awarded DTRA Contract to Develop Pathogen Detection and Identification Platform
Date:10/8/2010

PLEASANTON, Calif., Oct. 8 /PRNewswire/ -- IntegenX, Inc. (IXI) today announced that it has been awarded a new contract by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD) to develop an Integrated Sample-to-Sequence (ISS) system for rapid detection and identification of genetically engineered bacteria and viruses, medically relevant bacteria and viruses, and emerging pathogens. IntegenX will use its Universal Sample Preparation Module (USPM), created under a previous Department of Defense contract, to purify DNA from pathogen targets contained in complex matrices and present the purified material to an IntegenX library construction module, followed by an amplification module and a next-generation sequencing (NGS) module.

IntegenX will be the prime contractor for a first phase of $2.8 million and a possible 22-month, $14.8 million contract. The company will apply its patented MOVe™ technology to integrate the complete workflow of the ISS system, which will have a small footprint of less than 3 cubic feet and will be operated with minimal user interaction by a non-specialist.

"The ISS System will provide DoD and the country with a much-needed system to detect genetically engineered and emerging pathogens. This will help protect our country, and others, against genetically engineered bioagents. There is no system to detect such threats today," said Dr. Stevan Jovanovich, CEO and President of IntegenX.

"Our experience in next-generation sequencing library preparation and making a sample-to-answer system for forensic human identity testing has uniquely positioned IntegenX to accomplish the requirements that DTRA has requested," added Ezra van Gelder, Executive Vice President of Research and Development. "IntegenX technology integrates the processes to incorporate the complex steps into a complete and straightforward sample-to-sequence workflow."

About IntegenXIntegenX, Inc., headquartered in Pleasanton, CA, is a privately held company that designs, manufactures and markets automated DNA- and RNA-based sample preparation systems for life sciences, applied sciences, and diagnostics markets. IntegenX products eliminate the most acute pain points affecting widely adopted laboratory workflows. The company's expertise and intellectual property is based on its patented MOVe™ valve technology. The microfluidics technology platform integrates advanced fluidics and analytical robotic capabilities to produce sample-to-answer performance for DNA and RNA sequencing, DNA-based forensics and human identity (HID) testing, biodefense, as well as molecular diagnostics applications. The company's first commercial platform, the Apollo 100(TM) System, is used to optimally prepare DNA for sequencing. IntegenX will soon release the Apollo 324 system to resolve the fragmented workflows in next-generation sequencing library preparation. IntegenX has successfully tested a sample-to-answer platform for human DNA identification, slated for commercialization in 2011. For more information, please visit http://www.integenx.com.Contact:Howard D. GoldsteinIntegenX, Inc.5720 Stoneridge Drive, Suite 300Pleasanton, CA 94568925.701.3481howardg@integenX.com This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>

SOURCE IntegenX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Nanoimprint lithography NSF grant awarded to micro device lab at Stevens
2. BioNanomatrix Founder and CSO Dr. Han Cao Awarded Chinese Rising Star Entrepreneur Award
3. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease
4. YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension
5. PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
6. Genomas Awarded US Patent for its PhyzioGenomics Platform Technology to Predict Treatment Responses
7. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
8. Isolux Corsan Awarded a Contract for the Construction of an Ethanol Plant in Colombia
9. Laser pioneer Federico Capasso awarded Berthold Leibinger Zukunftspreis
10. San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry
11. Flad Architects Awarded Livermore Valley Open Campus Master Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... (NASDAQ: NBIX ) today announced its financial results for the ... --> --> For the fourth quarter of 2015, ... loss per share, compared to a net loss of $19.4 million, ... For the year ended December 31, 2015, the Company reported a ... compared to a net loss of $60.5 million, or $0.81 loss ...
(Date:2/11/2016)... -- Spectra BioPharma Selling Solutions (Spectra) is a new ... the experience, expertise, operational delivery and customer focus ... Created in concert with industry leading commercial experts, ... tactical needs of its clients by providing value-based ... and non-personal promotion. --> ...
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... new stem cell treatment clinic in Quito, Ecuador. The new facility will provide ... applications to patients from around the world. , The new GSCG clinic ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 Technology Enhancements ... presents an analysis of the digital and computed radiography ... Malaysia , and Indonesia ... trends and market size, as well as regional market ... country and discusses market penetration and market attractiveness, both ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
Breaking Biology News(10 mins):